Abstract 1753P
Background
Myxofibrosarcoma (MFS) are malignant tumors usually diagnosed in the extremities or trunk of elderly patients. Prognosis in this sarcoma subtype is dismal due to high risk of local recurrence. Our aim was to analyze the treatment results of patients (pts) diagnosed with localized myxofibrosarcoma, taking into account also surgical complications.
Methods
245 pts (51% male) with locally advanced myxofibrosarcoma treated in 2015-2020 were included in this retrospective analysis. Data on tumor characteristic and long-term survival and surgical complications were collected. Kaplan-Meier estimator with log-rank test was used for survival analysis. Median follow-up was 70 months (95%CI 67.2-79.7).
Results
The mean age was 63 years. 65% of the pts had no prior treatment, and 24% were referred after non-radical excision outside our center. Median size of the tumor was 9 cm (SD:6), 73% were high grade, 63% of cases were located on the lower limb (most often on the thigh). 82% had perioperative radiotherapy (72% preoperative). 22% of pts had preoperative chemotherapy. 76% pts underwent R0 resection, the others - R1. 56 pts (22%) had local recurrence and 29 of them had had another radical surgery, most of them extremity amputation (20 pts). 32% pts (79) developed metastases. Median OS was 115 months (95%CI 90.3-NA), while disease free-survival and local recurrence free survival (were 53.5 CI: (39.7 - NA) and not reached, respectively. In a multivariate analysis neoadjuvant radiotherapy was associated with longer LRFS (HR 0.36, 95%CI 0.21-0.65). T3 or T4 tumors and grade 2 or 3 tumors were associated with shorter DFS. Preoperative chemotherapy did not improve DFS (HR 0.82, 95%CI 0.51-1.33). 103 (42%) patient had complications after surgery resulting in prolonged wound healing, 40 of them had more than one complications, 10% patient required hospitalization due to complications, and 8.5% had another surgery for treatment of the complications.
Conclusions
Myxofibrosarcoma is a rare sarcoma subtype, local recurrences after adequate surgery are relatively common and most patient require adjuvant treatment and close follow-up. Treatment should be conducted in experienced sarcoma center with access to multidisciplinary team.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1730P - Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma
Presenter: NingNing Lu
Session: Poster session 06
Resources:
Abstract
1731P - Phase II study of the CDK2/4/6 inhibitor TQB3616 capsules in patients with dedifferentiated liposarcomas (DDLPS)
Presenter: Jing Chen
Session: Poster session 06
1732P - Primary pulmonary sarcoma: A EURACAN project
Presenter: Stephane Collaud
Session: Poster session 06
1733P - Update on gallant: A phase II study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab in previously treated sarcoma
Presenter: Neal Chawla
Session: Poster session 06
1734P - Evaluation of nivolumab in cutaneous angiosarcoma management: The ANGIOCHECK study
Presenter: Yasuhiro Fujisawa
Session: Poster session 06
1735P - Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial
Presenter: Zengjun Liu
Session: Poster session 06
Resources:
Abstract
1736P - An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)
Presenter: Edmund Bartlett
Session: Poster session 06
1737P - A comparison of the risk prediction models sarculator and PERSARC in patients with localized soft tissue sarcoma of the extremities and trunk wall
Presenter: Marthe Kobbeltvedt
Session: Poster session 06
1738P - Results from the conference on challenges in sarcoma (CCS) 2024
Presenter: Christian Rothermundt
Session: Poster session 06
1739P - Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part
Presenter: Erlinda Gordon
Session: Poster session 06